Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Triamcinolone vs Combination with 5-FU for Keloids and Hypertrophic Scars
NCT04812626Completed
- Sponsor
- B.P. Koirala Institute of Health Sciences
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of fluorouracil in keloid and Hypertrophic Scar (HS) (2 arms), sponsored by B.P. Koirala Institute of Health Sciences. Primary endpoints: Percentage of change in height of scar at 12 weeks, Percentage of reduction in The Patient and Observer Scar Assessment Score at 12 weeks and 2 more. Started Jan 2021; status: completed.
02
Drugs
fluorouracil
03
Conditions
keloidHypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT04812626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04812626.